Endoscopic ultrasound-guided biliary drainage versus percutaneous transhepatic biliary drainage after failed endoscopic retrograde cholangiopancreatography: a meta-analysis

Ramkaji Baniya
Sunil Upadhaya
Seetharamprasad Madala
Subash Chandra Subedi
Tabrez Shaik Mohammed
Ghassan Bachuwa
Hurley Medical Center, Michigan State University, Flint, MI, USA

Abstract: The failure rate of endoscopic retrograde cholangiopancreatography for biliary cannulation is approximately 6%–7% in cases of obstructive jaundice. Percutaneous transhepatic biliary drainage (PTBD) is the procedure of choice in such cases. Endoscopic ultrasound-guided biliary drainage (EGBD) is a novel technique that allows biliary drainage by echoendoscopy and fluoroscopy using a stent from the biliary tree to the gastrointestinal tract. Information in PubMed, Scopus, clinicaltrials.gov and Cochrane review were analyzed to obtain studies comparing EGBD and PTBD. Six studies fulfilled the inclusion criteria. Technical (odds ratio (OR): 0.34; confidence interval (CI) 0.10–1.14; \( p = 0.05 \)) and clinical (OR: 1.48; CI 0.46–4.79; \( p = 0.51 \)) success rates were not statistically significant between the EGBD and PTBD groups. Mild adverse events were nonsignificantly different (OR: 0.36; CI 0.10–1.24; \( p = 0.11 \)) but not the moderate-to-severe adverse events (OR: 0.16; CI 0.08–0.32; \( p \leq 0.00001 \)) and total adverse events (OR: 0.34; CI 0.20–0.59; \( p \leq 0.0001 \)). EGBD is equally effective but safer than PTBD.

Keywords: failed endoscopic retrograde cholangiopancreatography, percutaneous transhepatic biliary drainage, endoscopic ultrasound-guided biliary drainage, technical success, clinical success

Introduction
An estimated 500,000 endoscopic retrograde cholangiopancreatographies (ERCPs) are performed in the United States for diagnostic and therapeutic reasons.\(^1\,^2\) The failure rate of ERCP is approximately 6%–7% in cases of obstructive jaundice due to obstruction or altered anatomy.\(^3\,^4\) Surgical biliary decompression had been the mainstay of treatment for biliary decompression in such patients. However, it had significantly high morbidity and mortality in the postoperative period.\(^5\,^7\) Percutaneous transhepatic biliary drainage (PTBD) has a more favorable adverse events profile than surgical decompression but is associated with complications like fistula formation, repeat intervention, recurrent infection, and needs a long-term external catheter drainage, thereby leading to poor quality of life.\(^8\,^10\) Endoscopic ultrasound-guided biliary drainage (EGBD) is a novel technique that allows visualization and access of biliary tree by echoendoscopy and fluoroscopy, which was first described by Giovannini et al.\(^11\) It has the perceived benefits of being physiologic with anatomic internal drainage, improved comfort and recovery with less adverse events, and low cost.\(^12\) However, there are few studies published, to date, comparing the EGBD with PTBD
in terms of success rate and adverse events profile in cases of failed ERCP. Therefore, we conducted a meta-analysis to determine the aggregated efficacy and adverse events of EGBD and PTBD in such cases of failed ERCP.

**Methodology**

The Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) statement for reporting meta-analysis and systematic reviews as recommended by the Cochrane Collaborative was used for this meta-analysis (Figure 1). A comprehensive electronic literature search was conducted for all the clinical trials on treatment of failed ERCP-guided biliary decompression between the years 2000 and 2016 on PubMed, Scopus, Cochrane library and clinicaltrials.gov using all field “failed ERCP,” all field “Percutaneous biliary drainage” and all field “EUS-guided biliary drainage”; all three search headings were connected with Boolean operator “AND.” Studies published in English comparing EGBD with PTBD in cases of failed ERCP were included. Two hundred and ninety-two articles were found in the database. We included randomized controlled trials (RCTs), retrospective comparative studies and published abstracts reporting at least some adverse events. We excluded prospective non-RCTs, case reports, letters and comments. Studies were also excluded if the sample size was <20. Only human studies were included. A total of six studies met the above-mentioned criteria. Two studies were excluded as they included primary EGBD cases where ERCP was not tried as the primary procedure. A third study was excluded as they did not include the adverse event profile.

From the selected studies, we extracted the following baseline study details (Table 1): total number of patients enrolled, number of patients in each arm, mean age, gender ratio, comorbidity index, mean pre-procedural bilirubin, mean diameter of bile duct, etiology of biliary obstruction and reasons for ERCP failure. Technical and clinical success rates (Table 2) and adverse event profile (Table 3) were also

---

**Figure 1** PRISMA statement of the study.

**Abbreviations:** PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-Analysis; ERCP, endoscopic retrograde cholangiopancreatographic.
extracted from each study. The outcomes were calculated with RevMan, version 5.2 Windows (Cochrane Collaboration, Oxford, UK). Analysis was performed by Mantel–Haenszel test. Odds ratio (OR) was calculated using 95% confidence interval (CI). A randomized model was used because of the low heterogeneity from the low number of studies. A p-value of <0.05 was considered to be significant. Technical success rate was defined as successful catheter or stent placement. Clinical success was defined as resolution of biliary obstruction without the need for repeat intervention. Biloma and perihepatic bile collection, recurrent abdominal pain, subcapsular hematoma, pancreatitis, pneumoperitoneum, hemobilia and infection of drain site or sepsis were considered mild adverse events in all the studies. Similarly, sheared guide wire, bleeding, hepatic abscess, bile leak and peritonitis, cholangitis, cutaneous leak, tube malposition or

Table 1 Baseline characteristics, etiology of obstruction and reason for ERCP failure

<table>
<thead>
<tr>
<th>Studies</th>
<th>Artifon et al13</th>
<th>Bapaye et al14</th>
<th>Khashab et al15</th>
<th>Giovannini et al4</th>
<th>Lee et al16</th>
<th>Sharaiha et al12</th>
</tr>
</thead>
<tbody>
<tr>
<td>Type of study</td>
<td>Single-center prospective randomized controlled trial (Brazil)</td>
<td>Single-center retrospective comparative study (India)</td>
<td>Single-center retrospective comparative cohort study (USA)</td>
<td>Multicenter prospective randomized phase II trial (France)</td>
<td>Multicenter prospective randomized controlled trial (South Korea)</td>
<td>Single-center retrospective cohort review (USA)</td>
</tr>
<tr>
<td>Age (mean [SD]/ median ± SD), years</td>
<td>63.4 (11.1) vs 71.0 (11.9)</td>
<td>59.9 ± 13.3 vs 62.4 ± 10.2</td>
<td>64.9 ± 12.5 vs 66.9 ± 12.5</td>
<td>NA</td>
<td>66.5 vs 68.4</td>
<td>68.7 ± 13.9 vs 58.8 ± 13.6</td>
</tr>
<tr>
<td>Male:female ratio</td>
<td>2.25 vs 2.0</td>
<td>1.08 vs 1.6</td>
<td>1.2 vs 1.31</td>
<td>0.91 vs 9</td>
<td>3.25 vs 3</td>
<td>12 vs 1.47</td>
</tr>
<tr>
<td>Comorbidity/quality index (mean)</td>
<td>58.3 vs 57.8 (QoL SF 36)</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>40.7 vs 40.5</td>
<td>5.9 vs 6.4 (Charlson comorbidity index)</td>
</tr>
<tr>
<td>Total bilirubin (mean), mg/dL</td>
<td>16.4 vs 17.2</td>
<td>7.11 ± 7.6 vs 9.41 ± 12.4</td>
<td>15.8 ± 11.3 vs 14.5 ± 8.8</td>
<td>NA</td>
<td>NA</td>
<td>10.4 vs 11.8</td>
</tr>
<tr>
<td>Mean diameter of bile duct</td>
<td>13.7 vs 11.9</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>11.22 vs 12.6</td>
<td>NA</td>
</tr>
<tr>
<td>Etiology of obstruction</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pancreatic adenocarcinoma</td>
<td>10 vs 6</td>
<td>15 vs 18</td>
<td>43</td>
<td>NA</td>
<td>12 vs 12</td>
<td>22</td>
</tr>
<tr>
<td>Ampullary adenocarcinoma</td>
<td>1 vs 0</td>
<td>5 vs 3</td>
<td>3</td>
<td>NA</td>
<td>1 vs 0</td>
<td>3</td>
</tr>
<tr>
<td>Advanced lymphoma/ liposarcoma</td>
<td>0 vs 1</td>
<td>0</td>
<td>1</td>
<td>NA</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Plasmacytoma</td>
<td>1 vs 0</td>
<td>0</td>
<td>0</td>
<td>NA</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Cholangiocarcinoma</td>
<td>1 vs 1</td>
<td>2 vs 2</td>
<td>12</td>
<td>NA</td>
<td>7 vs 14</td>
<td>9</td>
</tr>
<tr>
<td>Gall bladder cancer</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>NA</td>
<td>5 vs 5</td>
<td>0</td>
</tr>
<tr>
<td>Gastric carcinoma</td>
<td>0 vs 1</td>
<td>0</td>
<td>1</td>
<td>NA</td>
<td>3 vs 2</td>
<td>4</td>
</tr>
<tr>
<td>Duodenal carcinoma</td>
<td>0</td>
<td>0</td>
<td>1</td>
<td>NA</td>
<td>3 vs 0</td>
<td>5</td>
</tr>
<tr>
<td>Metastasis</td>
<td>0 vs 3</td>
<td>0</td>
<td>12</td>
<td>NA</td>
<td>3 vs 1</td>
<td>7</td>
</tr>
<tr>
<td>Total malignancy</td>
<td>0</td>
<td>0</td>
<td>37</td>
<td>NA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Reason for ERCP failure</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inability of cannulation</td>
<td>16</td>
<td>42</td>
<td>0</td>
<td>NA</td>
<td>0</td>
<td>NA</td>
</tr>
<tr>
<td>Duodenal/stomach invasion</td>
<td>8</td>
<td>32</td>
<td>0</td>
<td>NA</td>
<td>22 vs 22</td>
<td>NA</td>
</tr>
<tr>
<td>Altered anatomy</td>
<td>1</td>
<td>9</td>
<td>0</td>
<td>NA</td>
<td>12 vs 10</td>
<td>NA</td>
</tr>
<tr>
<td>Indwelling duodenal stent</td>
<td>0</td>
<td>16</td>
<td>0</td>
<td>NA</td>
<td>0</td>
<td>NA</td>
</tr>
</tbody>
</table>

Abbreviations: ERCP, endoscopic retrograde cholangiopancreatography; NA, not available; QoL, quality of life; SD, standard deviation; SF 36, the 36-Item Short Form Health Survey.

Table 2 Technical and clinical success rates of the included studies

<table>
<thead>
<tr>
<th>Study</th>
<th>Technical success</th>
<th>Percutaneous transhepatic biliary drainage (PTBD)</th>
<th>Clinical success</th>
<th>Percutaneous transhepatic biliary drainage (PTBD)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Artifon et al13</td>
<td>13/13</td>
<td>12/12</td>
<td>13/13</td>
<td>12/12</td>
</tr>
<tr>
<td>Bapaye et al14</td>
<td>23/25</td>
<td>26/26</td>
<td>23/25</td>
<td>26/26</td>
</tr>
<tr>
<td>Khashab et al15</td>
<td>19/22</td>
<td>51/51</td>
<td>19/19</td>
<td>47/51</td>
</tr>
<tr>
<td>Giovannini et al4</td>
<td>19/20</td>
<td>17/17</td>
<td>18/19</td>
<td>17/17</td>
</tr>
<tr>
<td>Lee et al16</td>
<td>32/34</td>
<td>31/32</td>
<td>28/32</td>
<td>27/31</td>
</tr>
<tr>
<td>Sharaiha et al12</td>
<td>43/47</td>
<td>12/13</td>
<td>27/43</td>
<td>3/12</td>
</tr>
</tbody>
</table>

Abbreviations: EUS, endoscopic ultrasound; EGBD, endoscopic ultrasound-guided biliary drainage; PTBD, percutaneous transhepatic biliary drainage.
dysfunction and venous fistula were considered moderate adverse events, while cholecystitis and death were considered severe adverse events (Table 3).

**Result**

A total of 312 and 300 patients were analyzed for the technical and clinical success rates. Technical (odds ratio (OR): 0.34; CI 0.10–1.14; *p*=0.05; Figure 2A) and clinical (OR: 1.48; CI 0.46–4.79; *p*=0.51; Table 2B) success rates were not statistically significant between the EGBD and PTBD groups (Figure 2). Similarly, there was no significant difference in the mild adverse events profile between the two groups (OR: 0.36; CI 0.10–1.24; *p*=0.11; Figure 3A). On the contrary, the moderate and severe, and total adverse events were significantly less in the EGBD group (OR: 0.16; CI 0.08–0.32; *p*≤0.00001 and OR: 0.34; CI 0.20–0.59; *p*≤0.0001, respectively; Figure 3B). Cost analysis of the procedure was done in two studies.13,15 From both the studies, it was found that EGBD was less costly compared to PTBD (Table 3). The re-intervention rate was also less in the EGBD group for all the three studies reporting it (Table 3C).12,15,16

**Discussion**

The standard technique to access the biliary tree is ERCP. The success rate of bile duct cannulation by ERCP is over 90% in cases of unaltered upper gastrointestinal anatomy.15 The common reasons for the failed cannulation are altered or variant anatomy, ampullary pathology (stones, stenosis and tumor infiltration), periampullary diverticulum, gastric outlet obstruction, indwelling duodenal stent or previous gastric bypass surgery.9,21,22 Traditionally, such cases were managed with PTBD or surgery.23–27 The adverse events profile of these procedures is significantly high. Data show that drain occlusion, dislocation and cholangitis are the common complications with long-term PTBD therapy that lead to frequent interventions and long-term hospital stay.28 Also, patients are left with a long-term external drain which remains with the patients till the end of life, thereby, leading to poor quality of life.19 EGBD has emerged as a noble option that is feasible, extremely safe, efficacious and minimally invasive.29–34 This procedure involves accessing the biliary tree from within the lumen of the gastrointestinal system using echoendoscopy and fluoroscopy, creating a fistulous tract and deploying a stent in a single-step procedure, thus, obviating the need for external drain.22,35 However, the success rate and adverse events rate of this procedure were unknown. Our study shows that this procedure is safe and effective with the same technical and clinical success rate at skilled centers with better adverse events profile.

**Table 3 Adverse events of EGBD vs PTBD**

<table>
<thead>
<tr>
<th></th>
<th>Artifon et al13</th>
<th>Bapaye et al14</th>
<th>Khashab et al15</th>
<th>Giovannini et al4</th>
<th>Lee et al16</th>
<th>Sharaiha et al12</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Mild</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Perihepatic bile collection/biloma</td>
<td>1 vs 0</td>
<td>–</td>
<td>0 vs 7</td>
<td>–</td>
<td>0 vs 1</td>
<td></td>
</tr>
<tr>
<td>Recurrent abdominal pain</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>0 vs 3</td>
<td></td>
</tr>
<tr>
<td>Subcapsular hematoma</td>
<td>–</td>
<td>–</td>
<td>0 vs 2</td>
<td>–</td>
<td>–</td>
<td></td>
</tr>
<tr>
<td>Pancreatitis</td>
<td>–</td>
<td>–</td>
<td>1 vs 0</td>
<td>–</td>
<td>1 vs 0</td>
<td></td>
</tr>
<tr>
<td>Pneumoperitoneum</td>
<td>–</td>
<td>–</td>
<td>1 vs 0</td>
<td>–</td>
<td>1 vs 0</td>
<td></td>
</tr>
<tr>
<td>Hemobilia</td>
<td>–</td>
<td>–</td>
<td>0 vs 5</td>
<td>–</td>
<td>0 vs 1</td>
<td></td>
</tr>
<tr>
<td>Infection of drain site/sepsis</td>
<td>–</td>
<td>1 vs 2</td>
<td>0 vs 1</td>
<td>5 vs 7</td>
<td>0 vs 1</td>
<td></td>
</tr>
<tr>
<td>Perihepatic abscess</td>
<td>–</td>
<td>–</td>
<td>0 vs 1</td>
<td>–</td>
<td>0 vs 1</td>
<td></td>
</tr>
<tr>
<td><strong>Moderate</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sheared guide wire</td>
<td>–</td>
<td>–</td>
<td>1 vs 0</td>
<td>–</td>
<td>–</td>
<td></td>
</tr>
<tr>
<td>Bleeding</td>
<td>1 vs 0</td>
<td>0 vs 1</td>
<td>0 vs 1</td>
<td>1 vs 4</td>
<td>2 vs 1</td>
<td></td>
</tr>
<tr>
<td>Hepatic abscess</td>
<td>0 vs 2</td>
<td>–</td>
<td>0 vs 3</td>
<td>–</td>
<td>–</td>
<td></td>
</tr>
<tr>
<td>Bile leak/peritonitis</td>
<td>0 vs 1</td>
<td>4 vs 0</td>
<td>0 vs 10</td>
<td>1 vs 3</td>
<td>1 vs 4</td>
<td></td>
</tr>
<tr>
<td>Cholangitis</td>
<td>–</td>
<td>0 vs 2</td>
<td>0 vs 3</td>
<td>1 vs 3</td>
<td>0 vs 5</td>
<td></td>
</tr>
<tr>
<td>Cutaneous leak</td>
<td>–</td>
<td>0 vs 7</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td></td>
</tr>
<tr>
<td>Tube malposition/dysfunction</td>
<td>–</td>
<td>–</td>
<td>0 vs 2</td>
<td>–</td>
<td>0 vs 4</td>
<td></td>
</tr>
<tr>
<td>Venous fistula</td>
<td>–</td>
<td>–</td>
<td>0 vs 1</td>
<td>–</td>
<td>–</td>
<td></td>
</tr>
<tr>
<td><strong>Severe</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cholecystitis</td>
<td>–</td>
<td>–</td>
<td>1 vs 0</td>
<td>–</td>
<td>–</td>
<td></td>
</tr>
<tr>
<td>Re-intervention</td>
<td>–</td>
<td>–</td>
<td>15.7% vs 80.4%</td>
<td>–</td>
<td>11 vs 29</td>
<td></td>
</tr>
<tr>
<td>Death</td>
<td>–</td>
<td>1 vs 2</td>
<td>3 vs 3</td>
<td>–</td>
<td>–</td>
<td></td>
</tr>
<tr>
<td>Total adverse events</td>
<td>2 vs 3</td>
<td>6 vs 14</td>
<td>4 vs 36</td>
<td>11 vs 20</td>
<td>3 vs 10</td>
<td></td>
</tr>
<tr>
<td><strong>Cost of total procedure</strong></td>
<td>USD5673</td>
<td>NA</td>
<td>USD9218 ± 3772 vs</td>
<td>NA</td>
<td>NA</td>
<td></td>
</tr>
<tr>
<td>(median ± SD)</td>
<td>USD7570</td>
<td>NA</td>
<td>USD18,261 ± 16,021</td>
<td>NA</td>
<td>NA</td>
<td></td>
</tr>
</tbody>
</table>

**Note:** ‘–’ indicates not reported.

**Abbreviations:** EGBD, endoscopic ultrasound-guided biliary drainage; PTBD, percutaneous transhepatic biliary drainage; SD, standard deviation; NA, not available.
The result of our study shows a similar success rate of both the procedures at this time. A high technical and functional success rate has been obtained in most clinical studies, as observed in a systemic review by Wang et al, of 94.71% and 91.66%, respectively.36 This is partly because EGBD is being performed in high-volume centers by an experienced endoscopist. As the technique evolves, the success rate and the rate of complications of EGBD are bound to improve. At most centers, PTBD is an alternative procedure for failed ERCP. The development of EGBD, a technique that started just a decade ago as the fourth technique for biliary decompression (surgical drainage, percutaneous transhepatic drainage, endoscopic transpapillary drainage, EGBD), is currently replacing PTBD in high-volume centers.37 Although, at present, local expertise determines the type of technique used for biliary drainage in failed ERCP, EGBD is a less invasive and more physiologic technique. It provides better nutrition absorption, avoids electrolyte loss, requires fewer re-interventions and prevents the stress of external drain.38 If appropriate consent is obtained from the patient before ERCP, it can be done at a single setting.

EGBD is not without glitches. There are unique problems associated with EGBD at this time. This procedure is technically complex and diverse, with inherent risk of advanced endoscopy requiring specialized training and a steep learning curve.39 Therefore, EGBD is only feasible at high-volume therapeutic centers where appropriate interventional radiology and surgical backup are present.40 Otherwise, complications, such as bile leak, pneumoperitoneum, bleeding and stent

**Figure 2 (A)** Forest plot of technical success and **(B)** forest plot of clinical success.

Abbreviations: EGBD, endoscopic ultrasound-guided biliary drainage; PTBD, percutaneous transhepatic biliary drainage; M–H, Mantel–Haenszel test.
migration, are likely to occur.41,42 There is a small theoretical risk of introducing infection in EGBD because of the invasion of sterile biliary tree by transmural puncture from the luminal side of the gastrointestinal tract.43 But, the overall adverse events are bound to improve as in-roads are being made for this noble technique. Although labeled as rescue therapy for failed ERCP, primary EGBD is being currently compared to ERCP, and a recent study found comparable short-term outcomes of EGBD and ERCP.44 Also, unlike ERCP, there is no risk of postprocedural pancreatitis. In the hands of expert endoscopists, clinical success rate and complications have not been found to be different in the two groups.44,45

**Conclusion**

EGBD is an effective alternative procedure when ERCP fails in terms of success rate and adverse events profile.
the technique is evolving, EGBD is replacing PTBD as the standard procedure of choice in cases of failed ERCP.

Disclosure
The authors report that no conflicts of interest in this work.

References


